Illumina, a prominent name in the world of gene sequencing, has revealed its choice for the next chief executive, Jacob Thaysen. This appointment comes nearly three months after the former CEO’s departure, which occurred during a heated proxy battle with activist investor Carl Icahn.
The change in leadership follows the sudden resignation of Francis deSouza back in June. DeSouza’s departure was prompted by challenges from antitrust authorities in the U.S. and Europe regarding Illumina’s $7.1 billion acquisition of cancer-test developer Grail. This move drew the ire of Carl Icahn.
Jacob Thaysen, aged 48, is poised to take the reins of Illumina on September 25th, as announced by the company on Tuesday. Thaysen joins Illumina after a successful stint at Agilent Technologies, where he led its largest analytical lab unit.
Also Read: Ex-NBC Universal Ad Chief, Linda Yaccarino is New Twitter CEO
In his new role as CEO, Thaysen faces the significant challenge of navigating Illumina’s acquisition of Grail. DeSouza had encountered resistance from regulators regarding the deal and had proceeded with the multi-billion-dollar transaction, causing a sharp decline in the company’s stock value.
Illumina, headquartered in San Diego, has also disclosed that Thaysen will assume a seat on its board upon officially joining the company. Meanwhile, Charles Dadswell, who has been serving as Illumina’s interim CEO, will return to his position as Senior Vice President and General Counsel once Thaysen assumes the role of Chief Executive.
